Is Sarepta Therapeutics Inc (SRPT) A Good Stock To Buy?

With a general bullishness amongst the heavyweights, key hedge funds were breaking ground themselves. venBio Select Advisor, managed by Behzad Aghazadeh, initiated the biggest position in Sarepta Therapeutics Inc (NASDAQ:SRPT). venBio Select Advisor had $15.1 million invested in the company at the end of the quarter. Mark Kingdon’s Kingdon Capital also initiated a $3.2 million position during the quarter. The other funds with brand new SRPT positions are  John Overdeck and David Siegel’s Two Sigma Advisors and Paul Tudor Jones’s Tudor Investment Corp.

Let’s now take a look at hedge fund activity in other stocks – not necessarily in the same industry as Sarepta Therapeutics Inc (NASDAQ:SRPT) but similarly valued. These stocks are Scholastic Corp (NASDAQ:SCHL), Caleres Inc (NYSE:CAL), FibroGen Inc (NASDAQ:FGEN), and Halyard Health Inc (NYSE:HYH). This group of stocks’ market caps resemble SRPT’s market cap.

As you can see these stocks had an average of 16.5 hedge funds with bullish positions and the average amount invested in these stocks was $109 million. That figure was $307 million in SRPT’s case. Scholastic Corp (NASDAQ:SCHL) is the most popular stock in this table. On the other hand FibroGen Inc (NASDAQ:FGEN) is the least popular one with only 16 bullish hedge fund positions. Compared to these stocks Sarepta Therapeutics Inc (NASDAQ:SRPT) is more popular among hedge funds. Considering that hedge funds are fond of this stock in relation to its market cap peers, it may be a good idea to analyze it in detail and potentially include it in your portfolio.